As of Apr 20
| -0.35 / -0.72%|
The 8 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 54.00, with a high estimate of 70.00 and a low estimate of 42.00. The median estimate represents a +11.34% increase from the last price of 48.50.
The current consensus among 8 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.